Jürgen Mestan

8.3k total citations · 2 hit papers
56 papers, 5.1k citations indexed

About

Jürgen Mestan is a scholar working on Hematology, Molecular Biology and Rheumatology. According to data from OpenAlex, Jürgen Mestan has authored 56 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 18 papers in Molecular Biology and 15 papers in Rheumatology. Recurrent topics in Jürgen Mestan's work include Chronic Myeloid Leukemia Treatments (24 papers), Eosinophilic Disorders and Syndromes (15 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Jürgen Mestan is often cited by papers focused on Chronic Myeloid Leukemia Treatments (24 papers), Eosinophilic Disorders and Syndromes (15 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Jürgen Mestan collaborates with scholars based in Switzerland, United States and Germany. Jürgen Mestan's co-authors include Paul W. Manley, Sandra W. Cowan‐Jacob, Doriano Fabbro, Denise K. Walters, Michael C. Heinrich, Brian Druker, Thomas O’Hare, Francis Y. Lee, Michael W. Deininger and Eric P. Stoffregen and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Jürgen Mestan

56 papers receiving 4.9k citations

Hit Papers

In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-35... 2004 2026 2011 2018 2005 2004 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants
    2005 812 citations Thomas O’Hare, Denise K. Walters et al. Cancer Research profile →
  2. S6K1 −/− / S6K2 −/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway
    2004 623 citations Mario Pende, Sung Hee Um et al. Molecular and Cellular Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jürgen Mestan Switzerland 31 2.3k 1.8k 1.4k 1.1k 969 56 5.1k
Darren R. Veach United States 26 1.5k 0.7× 1.3k 0.7× 849 0.6× 1.0k 0.9× 543 0.6× 58 4.0k
Tomasz Skórski United States 46 3.8k 1.7× 3.1k 1.7× 1.8k 1.3× 1.7k 1.5× 809 0.8× 175 6.8k
Warren Fiskus United States 48 5.1k 2.3× 1.7k 0.9× 818 0.6× 1.2k 1.1× 223 0.2× 141 6.3k
Raymond Taetle United States 38 2.2k 1.0× 1.0k 0.6× 545 0.4× 1.2k 1.1× 156 0.2× 129 4.4k
CB Lozzio United States 6 2.3k 1.0× 1.3k 0.7× 781 0.6× 889 0.8× 157 0.2× 10 4.6k
BB Lozzio United States 6 2.3k 1.0× 1.3k 0.7× 780 0.6× 891 0.8× 157 0.2× 12 4.6k
Shinsuke Iida Japan 46 3.0k 1.3× 2.2k 1.2× 1.2k 0.9× 2.7k 2.4× 193 0.2× 331 7.8k
SJ Collins United States 27 3.8k 1.7× 2.1k 1.1× 472 0.3× 721 0.7× 179 0.2× 47 5.5k
Mark A. Dawson Australia 33 5.7k 2.5× 1.2k 0.6× 832 0.6× 1.3k 1.2× 183 0.2× 86 7.5k
Tessa L. Holyoake United Kingdom 59 3.8k 1.7× 7.5k 4.0× 4.7k 3.3× 2.2k 2.0× 2.1k 2.2× 219 11.1k

Countries citing papers authored by Jürgen Mestan

Since Specialization
Citations

This map shows the geographic impact of Jürgen Mestan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jürgen Mestan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jürgen Mestan more than expected).

Fields of papers citing papers by Jürgen Mestan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jürgen Mestan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jürgen Mestan. The network helps show where Jürgen Mestan may publish in the future.

Co-authorship network of co-authors of Jürgen Mestan

This figure shows the co-authorship network connecting the top 25 collaborators of Jürgen Mestan. A scholar is included among the top collaborators of Jürgen Mestan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jürgen Mestan. Jürgen Mestan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Beaufils, Florent, Vladimir Cmiljanović, Thomas Bohnacker, et al.. (2017). 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. Journal of Medicinal Chemistry. 60(17). 7524–7538. 115 indexed citations
2.
Skóra, Lukasz, Jürgen Mestan, Doriano Fabbro, Wolfgang Jahnke, & Stephan Grzesiek. (2013). NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proceedings of the National Academy of Sciences. 110(47). E4437–45. 92 indexed citations
3.
Manley, Paul W., Francesca Blasco, Jürgen Mestan, & Reiner Aichholz. (2013). The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588. Bioorganic & Medicinal Chemistry. 21(11). 3231–3239. 40 indexed citations
4.
Choi, Hwan Geun, Pingda Ren, Francisco Adrián, et al.. (2010). A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl. Journal of Medicinal Chemistry. 53(15). 5439–5448. 58 indexed citations
5.
Fabbro, Doriano, Paul W. Manley, Wolfgang Jahnke, et al.. (2010). Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1804(3). 454–462. 47 indexed citations
6.
7.
Adrián, Francisco, Qiang Ding, Taebo Sim, et al.. (2006). Allosteric inhibitors of Bcr-abl–dependent cell proliferation. Nature Chemical Biology. 2(2). 95–102. 290 indexed citations
8.
O’Hare, Thomas, Denise K. Walters, Eric P. Stoffregen, et al.. (2005). In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Research. 65(11). 4500–4505. 812 indexed citations breakdown →
9.
Manley, Paul W., Jürgen Mestan, Sandra W. Cowan‐Jacob, et al.. (2005). AMN107: Inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase. Cancer Research. 65. 1408–1408. 2 indexed citations
10.
Golemović, Mirna, Srđan Verstovšek, Francis J. Giles, et al.. (2005). AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia. Clinical Cancer Research. 11(13). 4941–4947. 162 indexed citations
11.
Pende, Mario, Sung Hee Um, Virginie Mieulet, et al.. (2004). S6K1 −/− / S6K2 −/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway. Molecular and Cellular Biology. 24(8). 3112–3124. 623 indexed citations breakdown →
12.
Ruetz, Stephan, François Natt, Jonathan Hall, et al.. (2004). The human ubiquitin-conjugating enzyme Cdc34 controls cellular proliferation through regulation of p27Kip1 protein levels. Experimental Cell Research. 303(2). 482–493. 22 indexed citations
13.
Manley, Paul W., Werner Breitenstein, Josef Brüggen, et al.. (2004). Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. Bioorganic & Medicinal Chemistry Letters. 14(23). 5793–5797. 47 indexed citations
14.
Cowan‐Jacob, Sandra W., Gabriele Fendrich, James I. Griffin, et al.. (2004). Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for Treatment. Mini-Reviews in Medicinal Chemistry. 4(3). 285–299. 120 indexed citations
15.
Griffin, James D., Doriano Fabbro, Gabriele Fendrich, et al.. (2004). AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.. Blood. 104(11). 551–551. 2 indexed citations
16.
Manley, Paul W., Pascal Furet, Guido Bold, et al.. (2002). Anthranilic Acid Amides:  A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors. Journal of Medicinal Chemistry. 45(26). 5687–5693. 83 indexed citations
17.
Fabbro, Doriano, Elisabeth Buchdunger, Jürgen Mestan, et al.. (1999). Inhibitors of Protein KinasesCGP 41251, a Protein Kinase Inhibitor with Potential as an Anticancer Agent. Pharmacology & Therapeutics. 82(2-3). 293–301. 122 indexed citations
18.
Fässler, Alexander, Guido Bold, Hans‐Georg Capraro, et al.. (1996). Aza-Peptide Analogs as Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors with Oral Bioavailability. Journal of Medicinal Chemistry. 39(16). 3203–3216. 54 indexed citations
19.
Mestan, Jürgen, Manfred Brockhaus, Holger Kirchner, & Henrik Jacobsen. (1988). Antiviral Activity of Tumour Necrosis Factor. Synergism with Interferons and Induction of Oligo-2',5'-adenylate Synthetase. Journal of General Virology. 69(12). 3113–3120. 62 indexed citations
20.
Esparza, Inmaculada, Andreas Ruppel, Jürgen Mestan, & Peter H. Krammer. (1988). Preactivation of Macrophages in Mice Acutely Infected with Schistosoma Mansoni. Immunobiology. 177(2). 105–119. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Darren R. Veach Breakdown of academic impact, for papers by Tomasz Skórski Breakdown of academic impact, for papers by Warren Fiskus Breakdown of academic impact, for papers by Raymond Taetle Breakdown of academic impact, for papers by CB Lozzio Breakdown of academic impact, for papers by BB Lozzio Breakdown of academic impact, for papers by Shinsuke Iida Breakdown of academic impact, for papers by SJ Collins Breakdown of academic impact, for papers by Mark A. Dawson Breakdown of academic impact, for papers by Tessa L. Holyoake
Rankless by CCL
2026